Merck KGaA Enters Deal With BenevolentAI, Exscientia for AI-Based Drug Discovery
2023年9月20日 - 3:05PM
Dow Jones News
By David Sachs
Merck KGaA said that it has partnered with BenevolentAI and
Exscientia on an initiative to discover more drugs with artificial
intelligence, which the company says will yield higher success
rates.
The German science and technology company said on Wednesday that
the partnership with the two U.K. AI firms includes access to an AI
platform to generate new drug candidates in oncology, cancer,
neurology and immunology. BenevolentAI and Exscientia will each
receive upfront payments for their work in the low double-digit
millions and will be eligible for additional payments depending on
net sales.
The deal includes three potential drug targets with the
possibility of more in the future, Merck said. Financial details
were not disclosed.
Write to David Sachs at david.sachs@wsj.com
(END) Dow Jones Newswires
September 20, 2023 01:50 ET (05:50 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Merck KGaA (PK) (USOTC:MKKGY)
過去 株価チャート
から 5 2024 まで 6 2024
Merck KGaA (PK) (USOTC:MKKGY)
過去 株価チャート
から 6 2023 まで 6 2024
Real-Time news about Merck KGaA (PK) (その他OTC): 0 recent articles
その他のMerck KGaA (PK)ニュース記事